This journal is
indexed in Scopus
Year 2013 Vol. 21 No 4
GENERAL AND SPECIAL SURGERY
F.G. NAZYROV, A.V. DEVYATOV, A.H. BABADZANOV, S.A. RAIMOV
PECULIARITIES OF DEVELOPMENT AND COURSE OF LIVER CIRRHOSIS COMPLICATIONS DEPENDING ON THE ETIOLOGICAL FACTOR
Republican Specialized Center of Surgery named after academician V.Vahidov
The Republic of Uzbekistan
Objectives. To study the peculiarities of the complications of liver cirrhosis (LC) depending on the etiological factors and to analyze the results of portosystemic shunting (PSSh) in these groups of patients.
Methods. The analysis covered the results of the PSSh in 309 cirrhotic patients with LC and portal hypertension (PH). All patients were divided into 4 groups: hepatitis “B”, “C”, HBV + HDV and chronic alcoholism.
Results. The performed analysis showed that for HBV-cirrhosis and especially for its combination with HDV-infection, a high incidence of clinically diagnosed hepatic encephalopathy and ascitic syndrome are considered to be the most typical. In turn, in case of HCV-cirrhosis and negative viral markers the risk of bleeding from the esophageal and gastric varices (EGV) predominates.
Conclusions. For HBV-cirrhosis and particularly for its combination with HDV-infection, high frequency of clinically diagnosed hepatic encephalopathy (24,7% and 33,3%) and ascitic syndrome (65,9% and 71,8%) are considered to be the most typical, while the incidence of bleeding from EGV is 53,8% and 56,4%, respectively. In turn, if HCV-cirrhosis and negative viral markers, clinical stages of hepatic encephalopathy detected in 18,9% and 20%, ascites in 47,2% and 45,7%, but the risk of bleeding reaches 71,7% and 51,4%, respectively. In cirrhotic patients HBV and HBV+HDV-etiology after PSSh the highest risk of developing liver failure (9,9-15,4%) and encephalopathy (63,4-84,2%) has been registered and the mortality rate reaches 3,3-5,1%. In case of HCV etiology cirrhosis surgery also contributes to poor functional status of hepatocytes, but the development of liver failure and encephalopathy is observed 1,5-2 folds rarely than in case of HBV and HBV + HDV-cirrhosis.
- Sadovnikova II. Tsirrozy pecheni. Voprosy etiologii, patogeneza, kliniki, diagnostiki, lecheniia [Cirrhosis of the liver. The etiology, pathogenesis, clinical manifestations, diagnosis, treatment]. RMZh. Pril: Bolezni Organov Pishchevareniia. 2003;5(2):37–42.
- Maier KP. Gepatit i posledstviia gepatita [Hepatitis and hepatitis consequences]: prakt ruk: per. s nem. Sheptulina AA, red. Moscow, RF: GEOTAR Meditsina; 2000. 432 p.
- Gish RG. Treating hepatitis C: the state of the art. Gastroenterol Clin North Am. 2004 Mar;33(1 Suppl):S1–9.
- -Pal'tsev MA, Anichkov NM. Patologicheskaia anatomiia [Pathological anatomy]: v 2 t. Moscow, RF: Meditsina; 2001;1. 528 p.
- de Franchis R, Dell'Era A, Fabris F, Iannuzzi F, Fazzini L, Sotela JC, Reati R, Primignani M. Medical treatment of portal hypertension. Acta Gastroenterol Belg. 2004 Oct-Dec;67(4):334–43.
- Alqahtani SA, Larson AM. Adult liver transplantation in the USA. Curr Opin Gastroenterol. 2011 May;27(3):240–47.
- Andreitseva OI. Vozmozhnosti ortotopicheskoi transplantatsii pecheni pri lechenii bol'nykh s terminal'nymi porazheniiami pecheni [Opportunities of orthotopic liver transplantation in the treatment of patients with terminal liver disease]. Sonsilium Medicum. 2004;6(6):25–27.
- Klupp J, Kohler S, Pascher A, Neuhaus P. Liver transplantation as ultimate tool to treat portal hypertension. Dig Dis. 2005;23(1):65–71.
- Jain A, Reyes J, Kashyap R, Dodson SF, Demetris AJ, Ruppert K, Abu-Elmagd K, Marsh W, Madariaga J, Mazariegos G, Geller D, Bonham CA, Gayowski T, Cacciarelli T, Fontes P, Starzl TE, Fung JJ. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg. 2000 Oct;232(4):490–500.
- Wroblewski T, Rowinski O, Ziarkiewicz-Wroblewska B, Gornicka B, Albrecht J, Jones EA, Krawczyk M. Two-stage transjugular intrahepatic porta-systemic shunt for patients with cirrhosis and a high risk of portal-systemic encephalopathy patients as a bridge to orthotopic liver transplantation: a preliminary report. Transplant Proc. 2006 Jan-Feb;38(1):204–08.
- Abraldes JG, Angermayr B, Bosch J. The management of portal hypertension. Clin Liver Dis. 2005 Nov;9(4):685–13, vii.
- Orloff MJ, Vaida F, Haynes KS, Hye RJ, Isenberg JI, Jinich-Brook H. Randomized controlled trial of emergency transjugular intrahepatic portosystemic shunt versus emergency portacaval shunt treatment of acute bleeding esophageal varices in cirrhosis. J Gastrointest Surg. 2012 Nov;16(11):2094–11.
- Rosemurgy AS, Frohman HA, Teta AF, Luberice K, Ross SB. Prosthetic H-graft portacaval shunts vs transjugular intrahepatic portasystemic stent shunts: 18-year follow-up of a randomized trial. J Am Coll Surg. 2012 Apr;214(4):445–53
100115, Respublika Uzbekistan, g. Tashkent, ul. Farkhadskaia, d. 10, Respublikanskii spetsializirovannyi tsentr khirurgii im. akad. V. Vakhidova, otdelenie khirurgii portal'noi gipertenzii i pankreatoduodenal'noi zony,
Babadzhanov Azam Khasanovich
Raimov S.A. An applicant for Doctor’s degree of the department of portal hypertension and pancreatoduodenal zone, Republican Specialized Center of Surgery named after academician V. Vahidov.
Babadzanov A.H. PhD, a senior researcher of the department of portal hypertension and pancreatoduodenal zone, Republican Specialized Center of Surgery named after academician V. Vahidov.
Devyatov A.V. MD, professor, a chief researcher of the department of portal hypertension and pancreatoduodenal zone, Republican Specialized Center of Surgery named after academician V. Vahidov.
Nazyrov F. G. Honored Worker of Public health care of the Republic of Uzbekistan, MD, professor, Academician of the Russian Academy of Natural Sciences, director of Republican Specialized Center of Surgery named after academician V. Vahidov, a head of the department of surgery of liver, biliary ducts, pancreatoduodenal zone and portal hypertension, vice-president of the Association of surgeons- hepatologists of CIS.